Breaking News Instant updates and real-time market news.

GILD

Gilead

$71.18

-0.67 (-0.93%)

, NK

NantKwest

$2.75

-0.97 (-26.08%)

04:55
11/11/18
11/11
04:55
11/11/18
04:55

Society for Immunotherapy of Cancer to hold annual meeting

SITC Annual Meeting 2018 will be held in Washington, D.C. on November 7-11.

GILD

Gilead

$71.18

-0.67 (-0.93%)

NK

NantKwest

$2.75

-0.97 (-26.08%)

AGEN

Agenus

$1.98

-0.08 (-3.88%)

ALPN

Alpine Immune Sciences

$4.80

-0.01 (-0.21%)

ALRN

Aileron Therapeutics

$1.91

-0.25 (-11.57%)

AZN

AstraZeneca

$40.97

0.33 (0.81%)

BLCM

Bellicum Pharmaceuticals

$4.34

-0.37 (-7.86%)

CLLS

Cellectis

$26.52

-0.42 (-1.56%)

CYAD

Celyad

$27.40

0.38 (1.41%)

CRVS

Corvus Pharmaceuticals

$7.95

-0.03 (-0.38%)

GSK

GlaxoSmithKline

$41.31

0.07 (0.17%)

MGNX

MacroGenics

$17.37

-0.88 (-4.82%)

NKTR

Nektar

$34.06

-1.24 (-3.51%)

SLS

Sellas Life Sciences

$1.82

-0.03 (-1.62%)

SYBX

Synlogic

$8.00

0.02 (0.25%)

ALKS

Alkermes

$37.68

-1.32 (-3.38%)

BYSI

BeyondSpring

$20.47

3.095 (17.81%)

CRSP

Crispr Therapeutics

$36.35

-1.34 (-3.56%)

INCY

Incyte

$66.04

-2.61 (-3.80%)

JNCE

Jounce Therapeutics

$4.82

-0.07 (-1.43%)

NLNK

NewLink Genetics

$2.08

-0.07 (-3.26%)

ONCS

OncoSec

$0.86

0.0073 (0.86%)

TSRO

Tesaro

$25.11

-5.7 (-18.50%)

FLDM

Fluidigm

$8.03

0.18 (2.29%)

FATE

Fate Therapeutics

$12.81

-0.775 (-5.71%)

EXEL

Exelixis

$16.66

-0.46 (-2.69%)

DNA

Bought by RHHBY

$0.00

(0.00%)

RCUS

Arcus Biosciences

$12.30

0.5 (4.24%)

PFE

Pfizer

$44.30

0.46 (1.05%)

KDMN

Kadmon

$2.65

-0.03 (-1.12%)

IMDZ

Immune Design

$1.47

-0.03 (-2.00%)

LLY

Eli Lilly

$112.22

2.17 (1.97%)

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 20

    Nov

  • 27

    Nov

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

  • 03

    Dec

  • 10

    Dec

  • 14

    Jan

  • 31

    Jan

GILD Gilead
$71.18

-0.67 (-0.93%)

10/31/18
MZHO
10/31/18
NO CHANGE
Target $94
MZHO
Buy
Mizuho says concerns over UnitedHealth program impact on Gilead seem unwarranted
Mizuho analyst Salim Syed blames UnitedHealth's (UNH) introduction of a new a program, called "My ScriptRewards," that will try to convince plan participants to take a cheaper HIV regimen in return for $500 in debit cards for the weakness in shares of Gilead (GILD). However, the analyst views the worries as unwarranted, noting that Cimduo is the "common thread" between all of the regimens that UnitedHealth's program calls out and it is an inferior drug to Gilead's Biktarvy. Biktarvy is the backbone of the number one recommended regimen according to HHS treatment guidelines, noted Syed, who keeps a Buy rating and $94 price target on Gilead shares.
10/31/18
EVER
10/31/18
NO CHANGE
EVER
Outperform
Gilead sales not at risk from UnitedHealth promotions, says Evercore ISI
Evercore ISI analyst Umer Raffat attributes the pullback today in shares of Gilead Sciences (GILD) to concerns over the company's HIV franchise given UnitedHealth's (UNH) promotions of cheaper alternatives. UnitedHealth (UNH) is offering a rewards plan to patients starting with HIV medications to help promote the use of lower priced drugs, Jefferies analyst Michael Yee pointed out earlier today in a research note. Raffat, however, does not see risk to Gilead's sales from the promotions. UnitedHealth's is proposing a switch to two separate tablets, which is not in the HIV guidelines today, says the analyst. He keeps an Outperform rating on Gilead shares, which are down 6% to $68.00 in afternoon trading.
10/26/18
JEFF
10/26/18
NO CHANGE
Target $95
JEFF
Buy
Gilead shares can rebound to $80 over next 6-9 months, says Jefferies
Jefferies analyst Michael Yee continues to think Gilead Sciences is being "underappreciated" following last night's "solid' Q3 results. Gilead is positioned well into 2019, Yee tells investors in a post-earnings research note. He sees several Phase III catalysts over the next 6-9 months that can help Gilead rebound back to $80 per share and closer to his unchanged price target of $95.
10/26/18
CANT
10/26/18
NO CHANGE
Target $88
CANT
Overweight
Cantor likes the setup for Gilead over the next six months
Cantor Fitzgerald analyst Alethia Young raised her price target for Gilead Sciences to $88 from $87 and reiterates an Overweight rating on the shares following last night's Q3 results. Gilead beat top and bottom line consensus expectations as the Biktarvy launch remains strong in HIV, Young tells investors in a post-earnings research note. She likes the setup for shares over the next six months, but acknowledges that investors may be waiting for new management to be in place. The analyst remains positive as she thinks pipeline expectations remain low.
NK NantKwest
$2.75

-0.97 (-26.08%)

10/16/18
SBSH
10/16/18
DOWNGRADE
SBSH
Sell
NantKwest downgraded to Sell from Neutral at Citi
10/17/18
SBSH
10/17/18
DOWNGRADE
Target $3
SBSH
Sell
Citi downgrades NantKwest to Sell on 'unwarranted' recent rally
Citi analyst Joel Beatty last night downgraded NantKwest to Sell from Neutral with an unchanged price target of $3. The analyst views the recent rally in the shares as "unwarranted" since he's not aware of any change in fundamentals. Beatty points out that NantKwest has a history of missing its own timelines for vaccine studies.
08/09/18
SBSH
08/09/18
UPGRADE
Target $3
SBSH
Neutral
NantKwest upgraded to Neutral from Sell at Citi
Citi upgraded NantKwest to Neutral with an unchanged price target of $3.
AGEN Agenus
$1.98

-0.08 (-3.88%)

10/19/18
HCWC
10/19/18
NO CHANGE
Target $36
HCWC
Buy
Xoma 'undeservedly and overly punished' after CRL, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Xoma (XOMA) to $36 from $49 after the company's partner Novartis (NVS) disclosed the receipt of a Complete Response Letter from the FDA in response to its application for the claim of cardiovascular risk reduction filed for canakinumab. Though canakinumab is one of the lead contributors to Xoma's valuation, the company's shares have been "undeservedly and overly punished," Pantginis tells investors in a research note. He remains focused on Xoma continuing to diversify its risk profile, highlighted by its recent Agenus (AGEN) transaction. He believes the company's numerous "shots on goal" present a "compelling opportunity" at current share levels.
ALPN Alpine Immune Sciences
$4.80

-0.01 (-0.21%)

09/27/18
09/27/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Overweight at JPMorgan. 2. UPS (UPS) initiated with a Sector Weight at KeyBanc. 3. Cigna (CI) initiated with an Overweight at Cantor Fitzgerald. 4. Restoration Robotics (HAIR) initiated with an Outperform at William Blair. 5. Alpine Immune Sciences (ALPN) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/13/18
RAJA
08/13/18
INITIATION
Target $13
RAJA
Outperform
Alpine Immune Sciences initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Alpine Immune Sciences (ALPN) with an Outperform and $13 price target. Benjamin said the company has a unique platform technology utilizing directed evolution to generate multi-functional single compounds. The analyst believes the platform is on the verge of a significant validation inflection point given a "slew" of preclinical results demonstrating activity in both autoimmune disease adn oncology, combined with early stage partnership with Kite, a Gilead (GILD) company.
09/27/18
PIPR
09/27/18
INITIATION
Target $12
PIPR
Overweight
Alpine Immune Sciences initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Alpine Immune Sciences with an Overweight rating and $12 price target. The company is developing proprietary variant Ig domain technology to create novel immunotherapies to treat cancer and autoimmune diseases, Tenthoff tells investors in a research note. He points out that Alpine ended Q2 with cash of $70 M and is trading at a market cap of only $88M.
06/28/18
OPCO
06/28/18
INITIATION
Target $13
OPCO
Outperform
Alpine Immune Sciences initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach started Alpine Immune Sciences with an Outperform rating and $13 price target, citing his belief that the company's differentiated platform technology could significantly improve the performance of checkpoint modulators, which have revolutionized the treatment of certain cancers and autoimmune disorders.
ALRN Aileron Therapeutics
$1.91

-0.25 (-11.57%)

AZN AstraZeneca
$40.97

0.33 (0.81%)

10/24/18
CANT
10/24/18
NO CHANGE
Target $68
CANT
Overweight
Cantor Fitzgerald sees nothing fundamental for Tesaro weakness
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating and $68 price target on Tesaro's (TSRO) shares as she sees nothing fundamental on recent weakness. While she acknowledges that the stock is down around 28% since ESMO, the analyst pointed out that the AstraZeneca's (AZN) SOLO1 data is a positive read for the niraparib PRIMA study that will read out in 2H 2019. Further, Young believes that key catalysts for Tesaro remain SITC - GARNET and AMBER data, pivotal data in endometrial for its PD-1 licensed from AnaptysBio (ANAB), and PRIMA data in first line ovarian in 2H 2019.
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Outperform
AstraZeneca reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated AstraZeneca with an Outperform.
10/22/18
CANT
10/22/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro price target raised to $68 from $57 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Tesaro (TSRO) to $68 saying AstraZeneca's (AZN) presented the Solo1 study using olaparib as a first-line treatment for BRCA ovarian cancer patients is positive for Tesaro's first-line study Prima study, with data expected in the second half of 2019. AstraZeneca's data clearly support broad use in first-line "at least" for BRCA ovarian cancer patients, which is positive for the PARP inhibitor class, Young tells investors in a research note. The analyst increased PARP inhibitor penetration in the BRCA patient at peak to 75% from 65% and reiterates an Overweight rating on Tesaro.
BLCM Bellicum Pharmaceuticals
$4.34

-0.37 (-7.86%)

03/14/18
JEFF
03/14/18
NO CHANGE
Target $16
JEFF
Buy
Bellicum clinical hold should lift soon, says Jefferies
Jefferies analyst Biren Amin says Bellicum Pharmaceuticals last night provided an update of its leading prgm BPX-501 with an "encouraging" survival rate at one year in pediatric acute myeloid leukemia patients. For BPX-601, management reported CART cell expansion in one pancreatic cancer patient following rimiducid administration, providing first patient validation of the company's activation switch, Amin tells investors in a post-earnings research note. The analyst notes Bellicum has also responded to FDA including proposed protocol changes. Amin believes the clinical hold should lift soon and keeps a Buy rating on Bellicum Pharmaceuticals with a $16 price target.
04/12/18
WELS
04/12/18
UPGRADE
Target $23
WELS
Outperform
Wells Fargo upgrades Bellicum to Outperform on lifting of clinical hold
Wells Fargo analyst Jim Birchenough last night upgraded Bellicum Pharmaceuticals to Outperform from Market Perform and raised his price target for the shares to $23 from $6. The shares in premarket trading are up 27% to $8.70 following news that the FDA lifted the clinical hold on studies of BPX-501 in the U.S. Rapid resolution of the clinical hold "substantially de-risks the investment," Birchenough tells investors in a research note. He believes Bellicum's platform for controllable cell therapies is well positioned for therapeutic oncology indications.
04/11/18
WELS
04/11/18
UPGRADE
WELS
Outperform
Bellicum Pharmaceuticals upgraded to Outperform at Wells Fargo
04/12/18
CANT
04/12/18
NO CHANGE
Target $18
CANT
Overweight
Bellicum price target raised to $18 from $10 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Bellicum Pharmaceuticals to $18 following the announcement of the FDA's lift of its U.S. clinical hold for BPX-501. The analyst now has increased confidence across the BPX-501 platform. He reiterates an Overweight rating on the shares.
CLLS Cellectis
$26.52

-0.42 (-1.56%)

07/16/18
LEHM
07/16/18
INITIATION
Target $50
LEHM
Overweight
Barclays starts Cellectis with Overweight rating, $50 price target
Barclays analyst Gena Wang initiated coverage of Cellectis S.A. with an Overweight rating and $50 price target. Following "impressive data" and several approvals of personalized autologous CAR-T cell therapies in various blood cancers, universal off-the-shelf allogeneic CAR-T would be future therapeutic approach with improved timeline, costs and homogeneity, Wang tells investors in a research note. As a leader in allo-CART with its proprietary Talen gene editing technology, Cellectis is the only company with clinical experience, on two programs, the analyst adds. She believes the company has a "strong" pipeline of allogeneic CAR-Ts targeting advanced blood cancers.
07/16/18
LEHM
07/16/18
INITIATION
Target $50
LEHM
Overweight
Cellectis initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Cellectis with an Overweight rating and $50 price target.
06/12/18
OPCO
06/12/18
NO CHANGE
Target $44
OPCO
Outperform
Cellectis price target raised to $44 from $40 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Cellectis to $44 from $40 after the company announced that the FDA approved its IND filing for UCART22 following a 30-day review period. The analyst reiterates an Outperform rating on the shares.
04/24/18
JEFF
04/24/18
NO CHANGE
Target $27
JEFF
Buy
Epizyme shares will bounce back, says Jefferies
Jefferies analyst Michael Yee says that while the partial clinical hold is a bad headline, shares of Epizyme (EPZM) will bounce back like Cellectis (CLLS), Juno and others did when they modified the protocol and trial brochures to get back up and running. After speaking to management, Yee thinks Epizyme's partial clinical hold will be lifted in a few months. Until then, however, the shares could be in the penalty box, the analyst tells investors in a research note. He keeps a Buy rating on Epizyme with a $27 price target.
CYAD Celyad
$27.40

0.38 (1.41%)

07/02/18
07/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Howard Hughes (HHC) initiated with a Buy at Jefferies. 2. Celyad (CYAD) initiated with a Buy at H.C. Wainwright. 3. Veoneer (VNE) initiated with a Sector Perform at RBC Capital. 4. Melinta Therapeutics (MLNT) initiated with an Overweight at Cantor Fitzgerald. 5. Axon (AAXN) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/02/18
HCWC
07/02/18
INITIATION
Target $45
HCWC
Buy
Celyad initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started Celyad with a Buy rating and $45 price target. The analyst believes the company has an "innovative CAR-T approach" with a "abundance of potential catalysts" in the second half of 2018.
10/30/18
WBLR
10/30/18
INITIATION
WBLR
Outperform
Celyad initiated with an Outperform at William Blair
William Blair analyst Raju Prasad started Celyad with an Outperform rating.
10/30/18
WBLR
10/30/18
INITIATION
WBLR
Outperform
William Blair starts Celyad with Outperform, $53 fair value estimate
William Blair analyst Raju Prasad initiated coverage of Celyad with an Outperform rating and $53 fair value estimate. Celyad's lead candidate, CYAD-01, is an autologous NKG2D chimeric antigen receptor (CAR)-T cell therapy being developed to treat both solid tumors and hematologic or liquid cancers, Prasad tells investors in a research note. The analyst believes the company's platform has several advantages, including a product profile that could be suitable for repeat injections, the ability to treat multiple tumor types using one CAR construct and the potential to show an adaptive immune response. Celyad's allogeneic platform is "significantly underappreciated," says Prasad.
CRVS Corvus Pharmaceuticals
$7.95

-0.03 (-0.38%)

08/15/18
08/15/18
UPGRADE
Target $15

Outperform
Corvus Pharmaceuticals upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Michael Morabito upgraded Corvus Pharmaceuticals to Outperform from Neutral and raised the stock's price target to $15 from $11 after assuming coverage of the name. The analyst believes the company's lead product, CPI-444, has a clear lead in the clinic compared to competitors, and looks like a compelling treatment for PD-1 refractory patients, a growing market with PD-1 therapy being used increasingly in first-line settings.
06/05/18
JEFF
06/05/18
INITIATION
Target $17
JEFF
Buy
Corvus Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Corvus Pharmaceuticals with a Buy rating and $17 price target. The analyst views CPI-444 as a potentially interesting immuno-oncology asset in non-small cell lung cancer and renal cell carcinoma.
08/15/18
FBCO
08/15/18
UPGRADE
FBCO
Outperform
Corvus Pharmaceuticals upgraded to Outperform from Neutral at Credit Suisse
GSK GlaxoSmithKline
$41.31

0.07 (0.17%)

10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
GlaxoSmithKline initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started GlaxoSmithKline with a Neutral rating and 1,679p price target, stating that he views its upside more in the consumer side than in pharma. The company's oncology and immunology pipeline could emerge, but it is still a bit early to tell, Fernandez added in his initiation note.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
GlaxoSmithKline reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated GlaxoSmithKline with a Peer Perform.
MGNX MacroGenics
$17.37

-0.88 (-4.82%)

04/06/18
LEER
04/06/18
INITIATION
Target $35
LEER
Outperform
MacroGenics assumed with an Outperform at Leerink
Leerink analyst Jonathan Chang assumed coverage of MacroGenics with an Outperform rating and $35 price target. The analyst views bispecific antibodies as a promising drug class and believes MacroGenics has one of the broadest and deepest pipelines of proprietary and partnered bispecific antibodies in clinical development. He has a positive view on the stock ahead of "multiple clinical catalysts" expected in 2018/2019.
03/05/18
03/05/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alta Mesa Resources (AMR) initiated with an Outperform at Imperial Capital. 2. Cactus (WHD) was initiated with an Overweight at Barclays, Piper Jaffray, and JPMorgan, an Outperform at Credit Suisse and a Buy at BofA/Merrill. 3. Victory Capital (VCTR) was initiated with an Overweight at Barclays, Morgan Stanley and JPMorgan, an Outperform at William Blair and RBC Capital, a Market Perform at Keefe Bruyette, a Buy at BofA/Merrill, a Neutral at Goldman Sachs, as well as a Hold at Sandler O'Neill. 4. Evolus (EOLS) was initiated with an Overweight at Cantor Fitzgerald, an Outperform at JMP Securities and a Buy at Mizuho and SunTrust. 5. MacroGenics (MGNX) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/31/18
EVER
05/31/18
INITIATION
Target $33
EVER
Outperform
MacroGenics initiated with an Outperform at Evercore ISI
Evercore ISI initiated MacroGenics with an Outperform and $33 price target.
09/10/18
BTIG
09/10/18
INITIATION
Target $30
BTIG
Buy
MacroGenics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed MacroGenics with a Buy rating and a price target if $30, saying he is positive on its DART and TRIDENT multi-functional antibodies programs and its Fc Optimization technology that "allows antibodies to interact more strongly with immune effector cells that resolve antibody-antigen complexes". The analyst contends that while the company's monoclonal antibodies, or mAb, development space is "crowded", MacroGenics offers "nearly two decades of tough won experience" and over two years of cash runway to give its "deep pipeline" multiple opportunities to "turn heads".
NKTR Nektar
$34.06

-1.24 (-3.51%)

11/08/18
HCWC
11/08/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar shares may have bottomed, says H.C. Wainwright
During last night's Q3 corporate update call, Nektar Therapeutics provided clarity on soon to be initiated Phase 3 programs, with a vital expansion cohort in second line non-small cell lung cancer, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. While the renal cell carcinoma, bladder, and melanoma studies were telegraphed previously, "clarity was welcome news for the bulls," says Chattopadhyay. However, the analyst adds that RCC and melanoma remain very crowded and that the initiation of triplet studies, if successfully clinically, "would significantly add to the financial toxicity discussion, especially since NKTR-214 is likely to be marketed as a unique medicine." Chattopadhyay thinks the newly defined cohort of approximately 100 second-line NSCLC patients to the ongoing Pivot trial is key to sentiment around the NKTR-214 story during the second half of 2019. He attributes the recent pullback in Nektar shares to disappointment from the preliminary read from the SITC abstract. Nonetheless, with a host of trial initiations and multiple combination updates at disease specific conferences during 2019, the stock may have bottomed, Chattopadhyay writes. However, the analyst says that while the study initiations and data releases should "quell some fears," the data quality "needs a pickup." He keeps a Neutral rating on Nektar with a $47 price target.
11/05/18
HCWC
11/05/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar price target lowered to $47 from $54 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Nektar Therapeuticsless than (NKTR) to $47 and keeps a Neutral rating on the shares. While the Phase 3 trial of Opdivo plus NKTR-214 is welcome news, the company faces a crowded frontline renal cell carcinoma treatment landscape and stiff commercial hurdles, Chattopadhyay tells investors in a research note. He believes that unless the NKTR-214 plus Opdivo combination is meaningfully superior to the Opdivo and Yervoy combination, Bristol-Myers (BMY) "may not be willing to muscle the commercial launch, given the cannibalization of its existing franchise."
11/06/18
PIPR
11/06/18
NO CHANGE
PIPR
Nektar abstract references old 50% ORR, says Piper Jaffray
The regular Society for Immunotherapy of Cancer abstract that provides an update of the first line melanoma patient cohort in the ongoing PIVOT-02 trial testing the combination of Nektar Therapeutics's NKTR-214 plus Opdivo was posted, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. He points out that 41 patients were enrolled with 38 evaluable for efficacy and the investigator-assessed objective response rate as of July 12 was 50%. Van Buren says that while is this is what we already knew, it confirms his prior assumption of the 50% response rate floor heading into the Friday afternoon updated data presentation. On Friday, the analyst expects to receive an updated response rate and more details on the quality of response. Finally, no responder has relapsed in this cohort and median duration of response has not been reached, which is promising as we begin to think about the probability of success for the Phase III trial, says the analyst. Shares of Nektar are down 7%, or $2.75, to $37.25 in pre-market trading.
11/08/18
JEFF
11/08/18
NO CHANGE
Target $73
JEFF
Buy
Nektar price target lowered to $73 from $103 at Jefferies
Jefferies analyst David Steinberg lowered his price target for Nektar Therapeutics (NKTR) to $73 after reducing his assumptions for NKTR-214 to reflect a potentially prolonged delay in non-small-cell lung carcinoma. The analyst, however, keeps a Buy rating on the shares following the company's Q3 results. He points out that Nektar's partnership with Bristol-Myers (BMY) as well as its other collaborations are ramping up.
SLS Sellas Life Sciences
$1.82

-0.03 (-1.62%)

07/31/18
HCWC
07/31/18
NO CHANGE
Target $4
HCWC
Buy
Sellas Life Sciences price target lowered to $4 from $11 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Sellas Life Sciences to $4 after updating his model and valuation to reflect the recent financing. The analyst keeps a Buy rating on the shares.
07/20/18
MAXM
07/20/18
NO CHANGE
Target $5
MAXM
Buy
Sellas Life Sciences price target lowered to $5 from $13 at Maxim
Maxim analyst Jason McCarthy lowered his price target on Sellas Life Sciences to $5 citing the impact of the company's capital raise and the resulting dilution. The analyst also kept his Buy rating, noting that the new valuation still represents "significant upside potential". With shares trading near 52-week lows and the cash runway now extended for the next round of catalysts, McCarthy says investors' focus now turns to Sellas' Galinpepimut-S program advancing toward the phase 3 study and the execution of the company's clinical programs.
11/01/18
11/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Roth Capital. 2. T-Mobile (TMUS) initiated with a Buy at Guggenheim. 3. Kosmos (KOS) initiated with a Buy at Berenberg. 4. Sellas Life Sciences (SLS) initiated with an Outperform at Oppenheimer. 5. OFS Credit (OCCI) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/18
OPCO
11/01/18
INITIATION
Target $13
OPCO
Outperform
Sellas Life Sciences initiated with an Outperform at Oppenheimer
Oppenheimer analyst Hartaj Singh started Sellas Life Sciences with an Outperform rating and $13 price target. With two late-stage clinical programs nearing pivotal trials and a robust early stage pipeline, the analyst believes Sellas Life Sciences is "highly undervalued" at sub-$50M in market cap. Cancer vaccines have had a convoluted history, but Singh believes this is an area for potential investor outperformance.
SYBX Synlogic
$8.00

0.02 (0.25%)

06/28/18
OPCO
06/28/18
INITIATION
Target $18
OPCO
Outperform
Synlogic initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach started Synlogic with an Outperform rating and $18 price target, stating that its two lead products - SYNB1020 and SYNB1618 - could have clinical proof-of-concept data within the next 12 months and that the company's platform is well positioned to attract collaborations and partnerships.
08/24/18
SBSH
08/24/18
UPGRADE
SBSH
Buy
Synlogic upgraded to Buy from Neutral at Citi
08/24/18
SBSH
08/24/18
UPGRADE
SBSH
Buy
Citi upgrades Synlogic to Buy after 28% pullback since July
Citi analyst Yigal Nochomovitz upgraded Synlogic to Buy from Neutral with an unchanged price target of $14. The stock has dropped 28% since July ahead of topline human proof-of-concept data expected by year-end for SYNB1020 in patients with elevated ammonia levels due to liver cirrhosis, Nochomovitz tells investors in a research note. The analyst, "for now," continues to assign a 15% probability of success for SYNB1020 in cirrhosis. However, he sees upside in the stock on positive data.
09/05/18
SBSH
09/05/18
NO CHANGE
Target $26
SBSH
Buy
Synlogic price target raised to $26 from $14 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Synlogic to $26 saying the Phase 1 data in healthy volunteers provides initial proof-of-concept for SYNB1618. Adverse events appeared manageable, Nochomovitz tells investors in a research note. The analyst keeps a Buy rating on Synlogic shares.
ALKS Alkermes
$37.68

-1.32 (-3.38%)

11/02/18
STFL
11/02/18
NO CHANGE
Target $40
STFL
Hold
Alkermes price target lowered to $40 from $44 at Stifel
Stifel analyst Paul Matteis removed any near-term credit for ALKS5461 from his model after a 3-20 advisory committee vote against substantial evidence of effectiveness in major depressive disorder. The advisory committee meeting firmed his view that the drug will not be approved during this review cycle, said Matteis, who keeps a Hold rating on Alkermes shares and lowered his price target to $40 from $44.
11/02/18
JPMS
11/02/18
NO CHANGE
JPMS
Overweight
Alkermes panel vote puts more pressure on ALKS 3831, says JPMorgan
The "decidedly negative" FDA panel vote yesterday for ALKS 5461, while unsurprising following the briefing documents, put "significantly more pressure" on the pending ALKS 3831 Phase 3 readout in schizophrenia later this quarter, JPMorgan analyst Cory Kasimov tells investors in a research note titled "ALKS Uphill Climb Fails to Reach the Summit." The analyst, however, believes yesterday's panel vote was broadly viewed as a "very high risk shot on goal" and notes he completely removed ALKS 5461 from his model last year. Nevertheless, "this is clearly not a great way to kick off a catalyst rich period for the company," says Kasimov. He has an Overweight rating on Alkermes and continues to estimate the fair value of the company's base business at $33 per share.
11/05/18
PIPR
11/05/18
INITIATION
Target $40
PIPR
Neutral
Alkermes initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Danielle Brill started Alkermes (ALKS) with a Neutral rating and $40 price target. The analyst says that while the shares are trading near 52-week lows, she struggles "to find something that will turn things around." She expects a positive data readout in Q4 from oral schizophrenia drug ALKS 3831, but believes this opportunity is already priced into shares. Proprietary pipeline sales will offset declining license and manufacturing agreement revenue, but Alkermes' overall annual growth "appears modest" at around 8%, Brill tells investors in a research note. She would start to get more constructive on the shares with signs of more robust revenue growth, such as indications that BIIB098 will be a big product for Biogen (BIIB), and/or Aristada successfully demonstrating superiority over Invega Sustenna in the ongoing head-to-head trial.
11/06/18
CANT
11/06/18
NO CHANGE
Target $41
CANT
Neutral
Alkermes price target lowered to $41 from $46 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner lowered his price target for Alkermes to $41 from $46 and reiterates a Neutral rating on the shares. The FDA advisory panel view of the ALKS 5461 NDA is a "major setback" not only for the drug but also to the ability of Alkermes to convince investors that the company can develop proprietary therapies of meaningful commercial potential, Tanner tells investors in a research note. He now believes the upcoming ALKS-3831 Enlighten-2 data release "looms larger" after the ALKS 5461 panel decision.
BYSI BeyondSpring
$20.47

3.095 (17.81%)

12/05/17
GHSC
12/05/17
INITIATION
Target $56
GHSC
Buy
BeyondSpring initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated BeyondSpring with a Buy and $56 price target saying its lead drug, Plinabulin, is a differentiated standard in the potential treatment option for chemotherapy-induced neutropenia (CIN). He thinks Plinabulin could also play a key role in improving results with traditional cancer drugs and immunotherapies that are limited by their significant toxicities.
03/01/18
HCWC
03/01/18
NO CHANGE
Target $60
HCWC
Buy
BeyondSpring recent selloff unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis views the 17.5% selloff in shares of BeyondSpring since the February 21 announced departure of CFO Richard Brand as unwarranted. After speaking to management, the analyst believes a new CFO will be a positive as the company moves closer to pivotal data and potential commercialization of Plinabulin. He keeps a Buy rating on BeyondSpring with a $60 price target.
03/19/18
HCWC
03/19/18
NO CHANGE
HCWC
BeyondSpring 'hits ground running' with Phase 3 study, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis noted that BeyondSpring just announced the initiation of its Phase 3 Study 105 non-inferiority head-to-head study of Plinabulin compared to Neulasta for prevention of docetaxel chemotherapy induced neutropenia. Pantginis sees a possible Plinabulin NDA filing with the China Food and Drug Administration within one year, and maintained a Buy rating and $60 price target on BeyondSpring shares.
CRSP Crispr Therapeutics
$36.35

-1.34 (-3.56%)

10/10/18
WELS
10/10/18
INITIATION
Target $65
WELS
Outperform
Crispr Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Crispr Therapeutics with an Outperform rating and $65 price target. The analyst cited the company's "highly leverageable" gene editing platform, "substantially de-risked" lead program in ex-vivo gene editing for beta thalassemia and sickle cell disease, a broad pipeline of both ex vivo and in vivo gene-editing opportunities, and strong collaborations balancing wholly owned programs to optimize future value creation.
10/10/18
10/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Take-Two (TTWO) initiated with an Outperform at Bernstein. 2. Shake Shack (SHAK) initiated with a Hold at Stifel. 3. Nu Skin (NUS) initiated with a Buy at DA Davidson. 4. Micron (MU) initiated with a Neutral at Piper Jaffray. 5. Crispr Therapeutics (CRSP) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
10/09/18
GUGG
10/09/18
INITIATION
GUGG
Neutral
Crispr Therapeutics assumed with a Neutral at Guggenheim
Guggenheim analyst Whitney Ijem assumed coverage of Crispr Therapeutics with a Neutral rating, saying the potential of Crispr's "highly innovative platform and diversified approach" is already reflected at current levels.
INCY Incyte
$66.04

-2.61 (-3.80%)

10/01/18
CANT
10/01/18
INITIATION
Target $73
CANT
Neutral
Incyte initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Incyte with a Neutral rating and $73 price target.
09/24/18
LEER
09/24/18
INITIATION
Target $78
LEER
Market Perform
Incyte initiated with a Market Perform at Leerink
Leerink analyst Andrew Berens started Incyte with a Market Perform rating and $78 price target.
10/22/18
RAJA
10/22/18
UPGRADE
RAJA
Strong Buy
Incyte upgraded to Strong Buy from Outperform at Raymond James
10/30/18
PIPR
10/30/18
NO CHANGE
Target $85
PIPR
Overweight
Incyte Q3 'not great,' but valuation 'very reasonable,' says Piper Jaffray
Although inventory destocking contributed to the Jakafi sales miss in Q3, it is never comforting to see a growth franchise report numbers that are essentially flat quarter-over-quarter, Piper Jaffray analyst Tyler Van Buren tells investors in a post-earnings research note titled "Q3 Results Weren't Great, But Larger 2019 Pipeline Readouts Are The Focus". However, the analyst says this negative impact has already reversed heading into Q4. He continues to believe that Incyte shares are trading at a "very reasonable valuation" based solely on the approved, revenue-generating drug franchise. Van Buren remains focused on the company's pipeline readouts in 2019 and reiterates an Overweight rating on the shares with an $85 price target.
JNCE Jounce Therapeutics
$4.82

-0.07 (-1.43%)

06/28/18
RAJA
06/28/18
INITIATION
Target $13
RAJA
Outperform
Jounce Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse initiated Jounce Therapeutics with an Outperform and $13 price target.
08/13/18
HCWC
08/13/18
NO CHANGE
Target $13
HCWC
Buy
Jounce Therapeutics price target lowered to $13 from $19 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Jounce Therapeutics to $13 but keeps a Buy rating on the shares. The analyst sees limited near-term catalysts to drive investor sentiment, and he believes there remains "substantial clinical questions that need to be addressed before ICOS agonism comes back to the fore."
06/05/18
COWN
06/05/18
DOWNGRADE
COWN
Market Perform
Jounce Therapeutics downgraded to Market Perform from Outperform at Cowen
06/04/18
06/04/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Big Lots (BIG) downgraded to Hold from Buy at Loop Capital with analyst Anthony Chukumba saying the company got off to a "tough start in fiscal 2018 with a store sales decline and continued slowdown in furniture sales." 2. Jounce Therapeutics (JNCE) downgraded to Neutral from Overweight at JPMorgan with analyst Cory Kasimov saying he views the company's ASCO data as disappointing. 3. MetLife (MET) downgraded to Neutral from Buy at Goldman Sachs with analyst Alex Scott saying he see slower progress towards return on equity improvement and believes some of the upside from capital return acceleration is behind the company at this point. 4. Dollar Tree (DLTR) downgraded to Accumulate from Buy at Gordon Haskett. 5. SM Energy (SM) downgraded to Neutral from Outperform at Credit Suisse with analyst Betty Jiang saying she believes SM Energy's discount valuation is appropriate given it has greater than average downside risk in a constrained Permian takeaway environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NLNK NewLink Genetics
$2.08

-0.07 (-3.26%)

08/01/18
08/01/18
DOWNGRADE
Target $4

Hold
NewLink Genetics downgraded to Hold on lower visibility at Stifel
As previously reported, Stifel analyst Stephen Willey downgraded NewLink Genetics to Hold from Buy, stating that the visibility going forward is increasingly limited given the limited amount of indoximod data generated to date in indications management now intends to pursue. He believes NewLink's strategic approach to AML carries substantial development, regulatory and commercial risk, Willey tells investors after the company announced the implementation of a restructuring plan. He lowered his price target on NewLink shares to $4 from $8.
08/01/18
STFL
08/01/18
DOWNGRADE
STFL
Hold
NewLink Genetics downgraded to Hold from Buy at Stifel
04/16/18
CANT
04/16/18
NO CHANGE
Target $7
CANT
Neutral
NewLink positive data unlikely to sway investors, says Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein reiterates a Neutral rating on NewLink Genetics (NLNK) with a $7 price target after the company over the weekend presented data from a Phase I study of indoximod in diffuse intrinsic pontine glioma. While positive, the data are unlikely to "sway investors at this point" given the recent failure of Incyte's (INCY) epacadostat, Goldstein tells investors in a research note.
04/09/18
04/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Westlake Chemical (WLK) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 2. Mettler-Toledo (MTD) downgraded to Neutral from Buy at Goldman Sachs with analyst Patrick Donnelly saying he sees an attractive fundamental backdrop across Tools but is more cautious on the outlook for sales upside at Mettler given his view of a likely moderation of growth in China after a year of catch-up investment in the region. Donnelly also highlights "tough comps" in Labs and Product inspection. 3. Franklin Resources (BEN) downgraded to Neutral from Buy at BofA/Merrill with analyst Michael Carrier saying Franklin's bottom half performance and continued outflows limits organic growth and multiple expansion. 4. NewLink Genetics (NLNK) downgraded to Neutral from Overweight at Cantor Fitzgerald and Baird as well as to Hold from Buy at Jefferies. 5. Incyte (INCY) downgraded to Hold from Buy at Gabelli with analyst Jing He citing the "surprising" failure of the Phase 3 ECHO-301 study in melanoma. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ONCS OncoSec
$0.86

0.0073 (0.86%)

10/15/18
PIPR
10/15/18
NO CHANGE
Target $5
PIPR
Overweight
Piper reiterates Overweight on OncoSec with $5 price target
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on OncoSec Medical with a $5 price target after the company announced it initiated a Phase II study of tavokinogene telseplasmid plus Keytruda in and triple negative breast cancer patients who have received one prior chemo or immunotherapy with preliminary data in 2019. The primary driver for OncoSec shares remains the Stage 1 Phase IIb Pisces data on tavokinogene telseplasmid plus Keytruda in PD-1 refractory melanoma in November, Tenthoff tells investors in a research note. He points out that depending on the data, OncoSec may initiate Stage 2 of the study, which could serve as the basis for accelerated approval in melanoma in 2020.
11/06/18
PIPR
11/06/18
NO CHANGE
Target $3
PIPR
Overweight
OncoSec price target lowered to $3 from $5 at Piper Jaffray
After OncoSec (ONCS) reported preliminary Phase 2b KEYNOTE-695 data for Tavo combined with Merck's (MRK) Keytruda in PD-1 refractory melanoma patients, Piper Jaffray analyst Edward Tenthoff said the data, while early, show evidence of clinical activity, adding that he believes duration of response data will be important. However, OncoSec shares are down 52% today, which Tenthoff attributes to the lower response rate compared to prior data in different patients. The analyst keeps an Overweight rating on OncoSec shares, but lowered his price target on the stock to $3 from $5 as he pushed out his approval projections for Tavo by one year in the U.S. and Europe.
11/07/18
HCWC
11/07/18
DOWNGRADE
Target $1
HCWC
Neutral
OncoSec downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju downgraded OncoSec to Neutral from Buy after the company reported preliminary top-line data from the PISCES/KEYNOTE-695 trial of TAVO with Keytruda in metastatic melanoma patients who have failed anti-PD-1 therapy, stating that his first impression is that the early efficacy results are "underwhelming." He noted that other second generation I/O agents have demonstrated higher response rates and while TAVO may eventually obtain regulatory approval, its efficacy may not be differentiated enough for wide market adoption. Selvaraju lowered his price target on OncoSec shares to $1 from $4.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $5
PIPR
Overweight
OncoSec price target raised to $5 from $4 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for OncoSec Medical to $5 saying tavokinogene telseplasmid has demonstrated proof-of-concept data in relapsed/refractory melanoma. The analyst expects final Phase II OMS-100 monotherapy plus preliminary Phase IIb data at the Society for Immunotherapy of Cancer meeting in November. Depending upon the strength of data in Stage 2 of this trial, OncoSec may be able to seek accelerated approval in melanoma in 2020, Tenthoff tells investors in a research note after taking over coverage of the name. He maintains Piper's Overweight rating on OncoSec.
TSRO Tesaro
$25.11

-5.7 (-18.50%)

11/09/18
PIPR
11/09/18
NO CHANGE
PIPR
Tesaro AMBER trial data incomplete, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond remained Neutral on Tesaro following what he calls "incomplete, if not disappointing" data for the company's AMBER trial evaluating anti-TIM-3 in combination with PD-1. That data, Raymond said, means waiting until 2019 for data from the higher dose arm. The analyst added that he has concerns on FY19 expectations for Tesaro's Zejula due to stagnating trends across the U.S. and the looming loss of full pricing in Germany next month, and is "comfortable remaining on the sidelines."
10/10/18
PIPR
10/10/18
NO CHANGE
Target $35
PIPR
Neutral
Tesaro raised Zejula 90-count capsule bottle price by 5%, says Piper Jaffray
According to Wolters Kluwer Health, Tesaro, effective today, took a 5% price increase on Zejula's 90-count capsule bottle, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst points out that in July, in the midst of a down-dosing effort aimed at reducing adverse events, management launched a 30-count capsule bottle at a 24% premium. Today's increase narrows that gap to 18%, and to the extent that physicians continue prescribing the 90-count capsule bottle, provides more confidence in Zejula's 2018 numbers, Raymond writes. He reiterates a Neutral rating on Tesaro shares with a $35 price target.
FLDM Fluidigm
$8.03

0.18 (2.29%)

11/02/18
PIPR
11/02/18
UPGRADE
Target $10
PIPR
Overweight
Fluidigm upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk upgraded Fluidigm to Overweight and raised his price target for the shares to $10 from $6.70. Mass Cytometry lead the beat in Q3 with both strong instrument placements and consumables growth while management remains confident on long-term adoption trends, Quirk tells investors in a post-earnings research note. The analyst is impressed with Mass Cytometry adoption and upgraded the shares to reflect that.
FATE Fate Therapeutics
$12.81

-0.775 (-5.71%)

09/18/18
PIPR
09/18/18
NO CHANGE
Target $25
PIPR
Overweight
Fate Therapeutics price target raised to $25 from $20 at Piper Jaffray
After Fate Therapeutics announced a collaboration with ONO Pharmaceutical for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates, Piper Jaffray analyst Edward Tenthoff said he likes the deal as it expands Fate's iPSC CAR-T pipeline while also giving the company $70M in near-term funding. Following the collaboration pact, Tenthoff increased his price target on Fate shares to $25 and reiterated an Overweight rating.
09/18/18
WELS
09/18/18
NO CHANGE
WELS
Fate Therapeutics platform validated with Ono deal, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on Fate Therapeutics after the company announced a deal with Ono Pharmaceuticals for induced pluripotent stem cell derived CAR T Therapeutics. The deal validates Fate's iPSC platform, should increase confidence in near term investigational new drug application clearance and provides support for its accelerating pipeline development, Birchenough tells investors in a research note. He reiterates an Outperform rating on Fate Therapeutics.
11/05/18
JEFF
11/05/18
INITIATION
Target $17
JEFF
Buy
Fate Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Fate Therapeutics with a Buy rating and $17 price target. Natural killer cells possess advantageous cytotoxic properties distinct from T cells, and have demonstrated clinical efficacy against select cancer types, Amin tells investors in a research note. The analyst says Fate "offers a unique and potentially disruptive approach."
09/25/18
PIPR
09/25/18
NO CHANGE
Target $23
PIPR
Overweight
Fate Therapeutics price target lowered to $23 from $25 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Fate Therapeutics to $23 to account for dilution from the equity issuance. He estimates Fate now holds proforma cash of $223M to advance and expand its clinical pipeline of off-the-shelf Natural Killer cell and CAR-T therapies. The analyst reiterates an Overweight rating on the shares.
EXEL Exelixis
$16.66

-0.46 (-2.69%)

11/02/18
NEED
11/02/18
NO CHANGE
Target $30
NEED
Buy
Exelixis well positioned for future I/O combos, says Needham
Needham analyst Chad Messer said cabozantinib is "becoming the drug of choice in second line treatment in RCC" and he believes immuno-oncology combos will support future growth. Exelixis is running several clinical programs investigating cabozantinib in combination with I/O drugs, noted Messer, who keeps a Buy rating and $30 price target on Exelixis following the company's Q3 report.
11/04/18
PIPR
11/04/18
NO CHANGE
Target $26
PIPR
Overweight
Exelixis price target lowered to $26 from $29 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Exelixis to $26 from $29, while reiterating an Overweight rating on the shares. The analyst notes the company delivered another beat with U.S. CABOMETYX sales of $158M in Q3. Although I-O is beginning to dominate front-line RCC, Tenthoff believes CABO is competitively positioned in certain patients and with ongoing I-O combo studies of its own. Next, he expects CABOMETYX label expansion in hepatocellular carcinoma with approval by the January 14th PDUFA date. The analyst now forecasts CABOMETYX sales of $595M in 2018, $826M in 2019, peaking at $1.38B in 2024.
09/21/18
PIPR
09/21/18
NO CHANGE
Target $29
PIPR
Overweight
Piper Jaffray reiterates Overweight rating on Exelixis after CHMP decision
After Ipsen (IPSEY) announced a positive CHMP decision for Cabometyx as a monotherapy for the treatment of hepatocellular carcinoma, Piper Jaffray analyst Edward Tenthoff noted that Exelixis (EXEL) is eligible for tiered royalties of 22-26% after $100M in sales of the drug in Europe. He expects final EMA approval in coming months and also expects the FDA to approve Cabometyx in liver cancer by the January 14 PDUFA date, Tenthoff tells investors. He reiterated an Overweight rating and $29 price target on Exelixis shares.
10/08/18
PIPR
10/08/18
NO CHANGE
PIPR
Piper Jaffray optimistic on Exelixis' Cabometyx
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $29 price target on Exelixis. The analyst noted that Exelixis initiated a Phase III trial of Cabometyx in radioiodine-refractory differentiated thyroid cancer, or DTC. He is looking for continued Cabometyx adoption in first and second-line renal cell carcinoma with sales of $572M this year, and sees Cabometyx approval in 2nd-line liver cancer by the January 14 PDUFA date, which will help drive sales to $873M in 2019.
DNA Bought by RHHBY
$0.00

(0.00%)

RCUS Arcus Biosciences
$12.30

0.5 (4.24%)

10/09/18
WEDB
10/09/18
INITIATION
Target $22
WEDB
Outperform
Arcus Biosciences initiated with an Outperform at Wedbush
Wedbush analyst Robert Driscoll started Arcus Biosciences with an Outperform rating and $22 price target. The analyst expects the company's focus on extensive biomarker analyses will allow for future clinical strategies with a high likelihood of success. Further, Driscoll believes the breadth and value of its pipeline is undervalued, and sees an attractive entry point ahead of initial efficacy data next year.
04/09/18
04/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Spirit Airlines (SAVE) initiated with a Neutral at UBS. 2. Northern Oil and Gas (NOG) initiated with a Buy at Stifel. 3. Camtek (CAMT) initiated with an Outperform at Northland. 4. Ares Management (ARES) initiated with a Buy at UBS. 5. Arcus Biosciences (RCUS) initiated with an Outperform at Leerink, a Buy at Citi, and a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/09/18
LEER
04/09/18
INITIATION
Target $21
LEER
Outperform
Arcus Biosciences initiated with an Outperform at Leerink
Leerink initiated Arcus Biosciences with an Outperform and $21 price target.
04/09/18
SBSH
04/09/18
INITIATION
Target $25
SBSH
Buy
Arcus Biosciences initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Arcus Biosciences with a Buy rating and $25 price target. The analyst says that while lead compound data is not expected until the first half of 2019, Arcus' proven management and drugs targeting validated pathway make the company competitive despite the crowded landscape in solid tumors.
PFE Pfizer
$44.30

0.46 (1.05%)

11/01/18
11/01/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Market Perform from Outperform at BMO Capital with analyst Alex Arfaei saying he maintains a positive view on the company longer-term but sees valuation at current levels reflecting its risk-reward profile. 2. Encana (ECA) downgraded to Underperformer from Neutral at CIBC. 3. New Oriental Education (EDU) downgraded to Hold from Buy at Deutsche Bank with analyst Tallan Zhou saying he expects "lingering margin pressure" following Q1 results. 4. Autoliv (ALV) downgraded to Neutral from Buy at Longbow with analyst Anthony Deem saying he sees the company's revenue growth being "very solid" through 2020 in mid-to-high single digit percentage territory, but he is less confident in positive operating leverage due to incremental cost overruns associated with new launches. 5. Aegion (AEGN) downgraded to Hold from Buy at Canaccord with analyst Chip Moore saying the company is a well positioned pipeline infrastructure play that is poised to benefit from attractive secular drivers longer-term, but the risk/reward is balanced at current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/06/18
SBSH
11/06/18
INITIATION
Target $25
SBSH
Sell
Solid Biosciences initiated with a Sell at Citi
Citi analyst Joel Beatty started Solid Biosciences (SLDB) with a Sell rating and $25 price target. The analyst believes the gene therapy agents in clinical development for Duchenne muscular dystrophy by Sarepta (SRPT) and Pfizer (PFE) will leave little market share to Solid Bio's SGT-001. The analyst forecasts Sarepta capturing the largest share of the DMD gene therapy market, followed by Pfizer, and then Solid.
11/01/18
BMOC
11/01/18
DOWNGRADE
Target $46
BMOC
Market Perform
Pfizer downgraded to Market Perform at BMO Capital on valuation
As reported earlier, BMO Capital analyst Alex Arfaei downgraded Pfizer to Market Perform from Outperform and lowered his price target to $46 from $47. The analyst maintains a positive view on the company longer-term but sees valuation at current levels reflecting its risk-reward profile. Arfaei points to potential headwinds facing Pfizer that include immuno-oncology R&D execution, along with disappointing sales from Prevnar, Ibrance, Xtandi, and Xeljanz. The analyst also believes that the positives of margin expansion and the prospects of Pfizer's pipeline assets like Tafamidis and Tanezumab are accounted by its stock price.
11/07/18
CHDN
11/07/18
NO CHANGE
Target $70
CHDN
Buy
uniQure price target raised to $70 from $50 at Chardan
Chardan analyst Gbola Amusa increased his price target on uniQure (QURE) to $70 from $50, stating that he believes the market is missing important dynamics in uniQure's favor over hemB competition from Pfizer (PFE) and Spark Therapeutics (ONCE). Amusa said uniQure's manufacturing is "much more scalable" than Pfizer's and he also believes uniQure's IP may cover the construct utilized by Pfizer. Amusa keeps a Buy rating on uniQure shares.
KDMN Kadmon
$2.65

-0.03 (-1.12%)

12/21/17
JEFF
12/21/17
NO CHANGE
Target $9
JEFF
Buy
Kadmon Q1 data could bring 'significant' upside, says Jefferies
Jefferies analyst Biren Amin believes Kadmon's Phase II data for KD025 in chronic graft-versus-host disease, expected in Q1 of 2018, represent "significant" upside with little downside risk. KD025 has shown "encouraging activity" in a difficult to treat population, Amin tells investors in a research note. He assumes U.S. market entry of KD025 for treatment of chronic graft-versus-host disease in 2020 and estimates U.S. peak sales of 333.1M. The analyst has a Buy rating on Kadmon shares with a $9 price target.
10/17/18
WBBS
10/17/18
UPGRADE
WBBS
Hold
Kadmon upgraded to Hold from Sell at WBB Securities
02/13/18
JEFF
02/13/18
NO CHANGE
Target $16
JEFF
Buy
Kadmon price target raised to $16 from $9 at Jefferies
Jefferies analyst Biren Amin raised his price target for Kadmon Holdings to $16 after the company announced positive data on its Phase II trial of KD025 in idiopathic pulmonary fibrosis. The absolute improvement of 127 mL between arms surpasses the bar of 45-85 mL seen with existing therapies and the shares should react positively, Amin tells investors in a research note. He keeps a Buy rating on Kadmon shares.
02/13/18
PIPR
02/13/18
NO CHANGE
Target $9
PIPR
Overweight
Kadmon price target raised to $9 after data on KD025 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff noted that Kadmon announced "positive" topline Phase 2 data on KD025 in 29 evaluable idiopathic pulmonary fibrosis, or IPF, patients. Upon adding value for KD025 in IPF, the analyst increased his price target on Kadmon shares to $9 from $7 and reiterated his Overweight rating on the stock.
IMDZ Immune Design
$1.47

-0.03 (-2.00%)

10/12/18
HCWC
10/12/18
NO CHANGE
Target $7.75
HCWC
Buy
Immune Design price target lowered to $7.75 from $11 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Immune Design to $7.75 after the company provided two updates to its corporate strategy. The company said its primary focus is being placed on G100 and the initial opportunity in indolent lymphoma patients and that CMB305 is being placed on the back burner following a review of the ongoing Phase 2 combination study with Tecentriq, and the strategic decision to not pursue the Synovate pivotal study in sarcoma patients, which is now discontinued, Pantginis tells investors in a research note. He believes the shares trading below cash "presents an opportunity to participate in the G100 program at ground floor levels." The analyst keeps a Buy rating on Immune Design.
10/12/18
RBCM
10/12/18
NO CHANGE
Target $11
RBCM
Outperform
Immune Design price target lowered to $11 from $15 at RBC Capital
RBC Capital analyst Brian Abrahams lowered his price target on Immune Design to $11 to reflect the impact of the company's announcement to focus on the development of intratumoral IO agent G100 and discontinue CMB305. The analyst adds that while the discontinuation is disappointing "given the promise of that tumor vaccine platform's mechanism", he also sees it a way to "refocus" the investment story and extend the company's cash runway. The analyst keeps his Outperform rating on Immune Design and maintains that shares are undervalued.
10/12/18
LEER
10/12/18
DOWNGRADE
LEER
Market Perform
Immune Design downgraded to Market Perform from Outperform at Leerink
08/29/18
08/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Weight Watchers (WTW) initiated with an Outperform at Oppenheimer. 2. Systemax (SYX) initiated with a Market Perform at William Blair. 3. Broadridge (BR) initiated with a Buy at SunTrust. 4. Mercury General (MCY) initiated with an Outperform at Keefe Bruyette. 5. Immune Design (IMDZ) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
LLY Eli Lilly
$112.22

2.17 (1.97%)

10/29/18
SBSH
10/29/18
NO CHANGE
Target $30
SBSH
Buy
Dicerna price target raised to $30 from $27 at Citi
Citi analyst Robyn Karnauskas said Dicerna's (DRNA) licensing and research collaboration with Eli Lilly (LLY) validates the former's RNAi platform and provides it with a meaningful cash infusion. The $200M upfront payment adds $3 to her discounted cash flow-derived price target, moving the target up to $30. Karnauskas keeps a Buy rating on Dicerna shares.
10/31/18
HCWC
10/31/18
NO CHANGE
Target $24
HCWC
Buy
Dicerna price target raised to $24 after Lilly, Alexion pacts at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target on Dicerna (DRNA) shares to $24 from $20 after the company announced collaborations with Eli Lilly (LLY) and Alexion Pharmaceuticals (ALXN). Arce views these partnerships as further strong validation of Dicerna's GalXC RNAi platform and keeps a Buy rating on the shares.
10/31/18
10/31/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Electric (GE) upgraded to Buy from Neutral at UBS with analyst Steven Winoker saying he has conviction that new CEO Larry Culp can lead a turnaround of the business and his upside/downside analysis for shares now stands at a favorable 3:1 skew following the recent selloff. 2. Eli Lilly (LLY) upgraded to Neutral from Underperform at Credit Suisse. 3. Comerica (CMA) upgraded to Strong Buy from Outperform at Raymond James with analyst David Long saying the pullback in the sector provides more attractive risk/reward in Comerica shares and said its deposit base is relatively attractive given its high 52% composition of noninterest-bearing deposits, 87.5% loan/deposit ratio, and low 21% cumulative deposit beta. 4. Denny's (DENN) upgraded to Overweight from Equal Weight at Stephens with analyst Will Slabaugh saying the company's transition to a 95%-plus franchised model, and the improving return on invested capital that accompanies the transition, should "command a higher valuation." 5. ASML (ASML) upgraded to Buy from Hold at Santander. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/18
FBCO
10/31/18
UPGRADE
FBCO
Neutral
Eli Lilly upgraded to Neutral from Underperform at Credit Suisse

TODAY'S FREE FLY STORIES

AKER

Akers Biosciences

$1.23

-0.365 (-22.88%)

09:16
11/19/18
11/19
09:16
11/19/18
09:16
Hot Stocks
Akers Biosciences considering business combinations in cannabis related industry »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APDN

Applied DNA Sciences

$1.08

-0.015 (-1.37%)

09:15
11/19/18
11/19
09:15
11/19/18
09:15
Hot Stocks
Applied DNA Sciences, Eurofins sign collaboration agreement »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REN

Resolute Energy

$30.51

0.67 (2.25%)

, VKTX

Viking Therapeutics

$11.65

0.27 (2.37%)

09:14
11/19/18
11/19
09:14
11/19/18
09:14
Hot Stocks
Fly Intel: Pre-market Movers »

HIGHER: Resolute Energy…

REN

Resolute Energy

$30.51

0.67 (2.25%)

VKTX

Viking Therapeutics

$11.65

0.27 (2.37%)

ZAYO

Zayo Group

$23.70

1.495 (6.73%)

LEJU

Leju

$1.71

0.05 (3.01%)

JD

JD.com

$23.04

-1.18 (-4.87%)

XEC

Cimarex Energy

$88.63

-0.27 (-0.30%)

PCG

PG&E

$24.39

6.62 (37.25%)

MDGL

Madrigal Pharmaceuticals

$129.47

-3.36 (-2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 03

    Dec

IRT

Independence Realty Trust

$9.99

0.21 (2.15%)

09:14
11/19/18
11/19
09:14
11/19/18
09:14
Initiation
Independence Realty Trust initiated  »

Independence Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACC

American Campus

09:14
11/19/18
11/19
09:14
11/19/18
09:14
Initiation
American Campus initiated  »

American Campus initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDR

UDR, Inc.

$41.06

0.6 (1.48%)

09:14
11/19/18
11/19
09:14
11/19/18
09:14
Initiation
UDR, Inc. initiated  »

UDR, Inc. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMRN

Immuron

$8.50

(0.00%)

, SGYP

Synergy Pharmaceuticals

$0.39

0.0211 (5.73%)

09:13
11/19/18
11/19
09:13
11/19/18
09:13
Hot Stocks
Immuron appoints Gary Jacob CEO »

Immuron (IMRN) announced…

IMRN

Immuron

$8.50

(0.00%)

SGYP

Synergy Pharmaceuticals

$0.39

0.0211 (5.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

INTC

Intel

$48.85

0.73 (1.52%)

09:12
11/19/18
11/19
09:12
11/19/18
09:12
Recommendations
Intel analyst commentary  »

Intel to benefit from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

OTEX

OpenText

$33.20

0.32 (0.97%)

09:10
11/19/18
11/19
09:10
11/19/18
09:10
Hot Stocks
Sun Chemical selects OpenText to improve customer service »

OpenText announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFIN

BankFinancial

$14.55

0.17 (1.18%)

09:09
11/19/18
11/19
09:09
11/19/18
09:09
Hot Stocks
BankFinancial extends, expands share repurchase program »

BankFinancial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMHC

Houghton Mifflin

$8.84

-0.12 (-1.34%)

09:09
11/19/18
11/19
09:09
11/19/18
09:09
Hot Stocks
Houghton Mifflin: Texas SBE approves new K-8 reading programs »

Houghton Mifflin Harcourt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEJU

Leju

$1.71

0.05 (3.01%)

09:06
11/19/18
11/19
09:06
11/19/18
09:06
Earnings
Breaking Earnings news story on Leju »

Leju sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LEJU

Leju

$1.71

0.05 (3.01%)

09:06
11/19/18
11/19
09:06
11/19/18
09:06
Earnings
Leju reports Q3 adj. EPS 8c, one estimate (2c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

GLYC

GlycoMimetics

$11.94

0.34 (2.93%)

09:05
11/19/18
11/19
09:05
11/19/18
09:05
Hot Stocks
GlycoMimetics enrolls first patient in Phase 3 clinical trial of uproleselan »

GlycoMimetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$82.54

0.25 (0.30%)

, CVS

CVS Health

$79.33

-0.48 (-0.60%)

09:05
11/19/18
11/19
09:05
11/19/18
09:05
Hot Stocks
Florida AG amends opioid lawsuit complaint to include Walgreens, CVS »

Attorney General Pam…

WBA

Walgreens Boots Alliance

$82.54

0.25 (0.30%)

CVS

CVS Health

$79.33

-0.48 (-0.60%)

INSY

Insys Therapeutics

$7.08

-0.13 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

DISH

Dish

$32.85

-0.25 (-0.76%)

, CTL

CenturyLink

$19.16

0.19 (1.00%)

09:02
11/19/18
11/19
09:02
11/19/18
09:02
Hot Stocks
Dish names Atilla Tinic as Chief Information Officer »

DISH (DISH) announced…

DISH

Dish

$32.85

-0.25 (-0.76%)

CTL

CenturyLink

$19.16

0.19 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

AVNW

Aviat Networks

$14.92

-0.43 (-2.80%)

, MSI

Motorola Solutions

$129.97

0.72 (0.56%)

09:01
11/19/18
11/19
09:01
11/19/18
09:01
Hot Stocks
Aviat Networks selected by Motorola Solutions for Florida's P25 network »

Aviat Networks (AVNW)…

AVNW

Aviat Networks

$14.92

-0.43 (-2.80%)

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 18

    Dec

  • 19

    Dec

YETI

Yeti

$16.99

0.1 (0.59%)

09:00
11/19/18
11/19
09:00
11/19/18
09:00
Initiation
Yeti initiated  »

Yeti initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

GE

General Electric

$8.04

-0.135 (-1.65%)

08:57
11/19/18
11/19
08:57
11/19/18
08:57
Hot Stocks
GE announces new leadership in Power reorganization »

GE recently announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$8.04

-0.135 (-1.65%)

, FB

Facebook

$139.55

-4.31 (-3.00%)

08:55
11/19/18
11/19
08:55
11/19/18
08:55
Options
Notable open interest changes for November 19th »

Friday's total…

GE

General Electric

$8.04

-0.135 (-1.65%)

FB

Facebook

$139.55

-4.31 (-3.00%)

NVDA

Nvidia

$164.38

-38.27 (-18.88%)

JD

JD.com

$23.04

-1.18 (-4.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 26

    Nov

  • 28

    Nov

  • 10

    Dec

BKI

Black Knight

$49.77

0.87 (1.78%)

08:55
11/19/18
11/19
08:55
11/19/18
08:55
Conference/Events
Black Knight to host Investor Day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 03

    Dec

ENR

Energizer

$49.91

-1.53 (-2.97%)

, SPB

Spectrum Brands

$59.36

0.87 (1.49%)

08:54
11/19/18
11/19
08:54
11/19/18
08:54
Recommendations
Energizer, Spectrum Brands analyst commentary  »

Energizer price target…

ENR

Energizer

$49.91

-1.53 (-2.97%)

SPB

Spectrum Brands

$59.36

0.87 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

, RAD

Rite Aid

$1.22

0.01 (0.83%)

08:50
11/19/18
11/19
08:50
11/19/18
08:50
Recommendations
Amazon.com, Rite Aid, Walgreens Boots Alliance, CVS Health analyst commentary  »

Jefferies uncovers signs…

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

RAD

Rite Aid

$1.22

0.01 (0.83%)

WBA

Walgreens Boots Alliance

$82.54

0.25 (0.30%)

CVS

CVS Health

$79.33

-0.48 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 02

    Dec

  • 04

    Dec

WP

Worldpay

$82.05

-0.62 (-0.75%)

08:50
11/19/18
11/19
08:50
11/19/18
08:50
Recommendations
Worldpay analyst commentary  »

Worldpay elevated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

08:50
11/19/18
11/19
08:50
11/19/18
08:50
General news
U.S. equities are back under pressure »

U.S. equities are back…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.